134 related articles for article (PubMed ID: 32737698)
1. Prognostic Significance of Complete Pathologic Response Obtained with Chemotherapy Versus Chemoradiotherapy in Gastric Cancer.
Trumbull DA; Lemini R; Díaz Vico T; Jorgensen MS; Attwood K; Ji W; Brady M; Gabriel E; Kukar M
Ann Surg Oncol; 2021 Feb; 28(2):766-773. PubMed ID: 32737698
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
[TBL] [Abstract][Full Text] [Related]
4. An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma.
Cools-Lartigue J; Markar S; Mueller C; Hofstetter W; Nilsson M; Ilonen I; Soderstrom H; Rasanen J; Gisbertz S; Hanna GB; Elliott J; Reynolds J; Kisiel A; Griffiths E; Van Berge Henegouwen M; Ferri L
Ann Surg; 2022 Nov; 276(5):799-805. PubMed ID: 35861351
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
[TBL] [Abstract][Full Text] [Related]
7. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
8. The differential effect of neoadjuvant chemotherapy and chemoradiation on nodal downstaging in pancreatic adenocarcinoma.
Altimari M; Wells A; Abad J; Chawla A
Pancreatology; 2023 Nov; 23(7):805-810. PubMed ID: 37599170
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Klevebro F; Alexandersson von Döbeln G; Wang N; Johnsen G; Jacobsen AB; Friesland S; Hatlevoll I; Glenjen NI; Lind P; Tsai JA; Lundell L; Nilsson M
Ann Oncol; 2016 Apr; 27(4):660-7. PubMed ID: 26782957
[TBL] [Abstract][Full Text] [Related]
10. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemoradiation Shows No Survival Advantage to Chemotherapy Alone in Stage IIIA Patients.
Krantz SB; Mitzman B; Lutfi W; Kuchta K; Wang CH; Howington JA; Kim KW
Ann Thorac Surg; 2018 Apr; 105(4):1008-1016. PubMed ID: 29453000
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Chemoradiotherapy Versus Chemotherapy for the Treatment of Locally Advanced Esophageal Adenocarcinoma in the European Multicenter ENSURE Study.
Elliott JA; Klevebro F; Mantziari S; Markar SR; Goense L; Johar A; Lagergren P; Zaninotto G; van Hillegersberg R; van Berge Henegouwen MI; Schäfer M; Nilsson M; Hanna GB; Reynolds JV;
Ann Surg; 2023 Nov; 278(5):692-700. PubMed ID: 37470379
[TBL] [Abstract][Full Text] [Related]
13. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
[TBL] [Abstract][Full Text] [Related]
14. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
[TBL] [Abstract][Full Text] [Related]
15. Do treated rectal tumors appear differently on MRI after chemotherapy versus chemoradiotherapy?
Shen Y; Wen Y; Bi L; Yang X; Gong X; Deng X; Meng W; Wang Z
Abdom Radiol (NY); 2024 Mar; 49(3):774-782. PubMed ID: 37999742
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma.
Chen Y; Wu X; Hao D; Cheng X; Zhang L; Zhang Y; Ke S; Shi W; He C
Oncotarget; 2019 Jun; 10(40):4069-4078. PubMed ID: 31258850
[TBL] [Abstract][Full Text] [Related]
17. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer.
He F; Yu L; Ding Y; Li ZH; Wang J; Zheng J; Chen HY; Liu S; Pang XL; Ajani JA; Wan XB
Cancer Sci; 2020 Nov; 111(11):4205-4217. PubMed ID: 32860448
[TBL] [Abstract][Full Text] [Related]
18. Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastro-esophageal junction from a tertiary cancer care center in India.
Rao T S; Raju KVVN; Patnaik SC; Reddy P; Saksena AR; Rajappa S; Mallavarapu KM; Santa A; Gudipudi D; Boleneni N; Usofi Z; Gujjuru S; Smith L; Are C; Nusrath S
J Surg Oncol; 2021 Jun; 123(7):1547-1557. PubMed ID: 33650697
[TBL] [Abstract][Full Text] [Related]
19. Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis.
Jing SW; Qin JJ; Liu Q; Zhai C; Wu YJ; Cheng YJ; Czito BG; Wang J
Future Oncol; 2019 Jul; 15(20):2413-2422. PubMed ID: 31269806
[No Abstract] [Full Text] [Related]
20. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]